A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
← catalyst calendarNCT07085104 · readout ≤ 559 d
Sponsored by Allogene Therapeutics (industry) · ALLO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
66estimated
Sites
15
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-13 | actual | When the study began enrolling |
| Primary completion | Feb 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Lupus Erythematosus (With and Without Nephritis)
- Idiopathic Inflammatory Myopathy
- Systemic Sclerosis
Interventions
- Genetic: ALLO-329
- Drug: Cyclophosphamide
- Drug: Fludarabine
Primary outcome
what the primary-completion date above is the date OFIncidence of Dose Limiting toxicities (DLTs) and Other Safety Parameters
measured Up to 60 months
Permalink · ALLO's whole pipeline · Catalyst calendar · Every registered study · What changed